Portal de Periódicos da CAPES

Neoadjuvant Therapy Before Radical Prostatectomy For Clinical T3/T4 Carcinoma of the Prostate: 5-Year Followup, Phase II Southwest Oncology Group Study 9109

2002; Lippincott Williams & Wilkins; Volume: 168; Issue: 5 Linguagem: Inglês

10.1016/s0022-5347(05)64285-1

1527-3792

Isaac J. Powell, Catherine M. Tangen, Gary J. Miller, Bruce A. Lowe, Gabriel P. Haas, Peter R. Carroll, Michael B. Osswald, Ralph Devere White, Ian M. Thompson, E. David Crawford,

Advanced Radiotherapy Techniques

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Nov 2002Neoadjuvant Therapy Before Radical Prostatectomy For Clinical T3/T4 Carcinoma of the Prostate: 5-Year Followup, Phase II Southwest Oncology Group Study 9109 ISAAC J. POWELL, CATHERINE M. TANGEN, GARY J. MILLER, BRUCE A. LOWE, GABRIEL HAAS, PETER R. CARROLL, MICHAEL B. OSSWALD, RALPH deVERE WHITE, IAN M. THOMPSON, and E. DAVID CRAWFORD ISAAC J. POWELLISAAC J. POWELL , CATHERINE M. TANGENCATHERINE M. TANGEN , GARY J. MILLERGARY J. MILLER , BRUCE A. LOWEBRUCE A. LOWE , GABRIEL HAASGABRIEL HAAS , PETER R. CARROLLPETER R. CARROLL , MICHAEL B. OSSWALDMICHAEL B. OSSWALD , RALPH deVERE WHITERALPH deVERE WHITE , IAN M. THOMPSONIAN M. THOMPSON , and E. DAVID CRAWFORDE. DAVID CRAWFORD View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)64285-1AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Several investigators have examined the role of hormonal therapy before definitive local therapy for locally advanced prostate cancer to improve outcome. We evaluated the resectability rate and clinical response rate to 16 weeks of total androgen blockage therapy for clinically locally prostate cancer before radical prostatectomy, and progression-free survival in this multi-institutional study. Materials and Methods: Southwest Oncology Group 9109 was a phase II feasibility study designed to treat patients with clinical stage C prostate cancer (T3, T4, N0 and M0). Cases were classified by stage T3 versus T4 and bulky (greater than 4 cm.) versus nonbulky (or less 4 cm.) disease. The neoadjuvant agents used were goserelin and flutamide before radical prostatectomy. Results: A total of 62 patients were accrued to the study and 1 patient was ineligible. There were 2 protocol deviations and these patients refused to undergo prostatectomy after hormonal therapy. Four patients went off protocol treatment because they were not considered surgical candidates. The racial distribution was 72% white, 20% black, 7% Hispanic and 2% Asian. Clinical stage at diagnosis was T3 in 97% and T4 in 3% of cases. Of the patients 39% were diagnosed with bulky disease. Of the 61 eligible patients 55 (90%) underwent a prostatectomy. The 5-year progression-free survival estimate was 70% (24 of 61 cases failed) and the 5-year survival estimate was 90% (11 of 61 deaths). Most of the patients in this trial would have been considered inoperable and referred to radiation oncology. Conclusions: Neoadjuvant hormonal therapy followed by radical prostatectomy is reasonable and appropriate for clinical stage T3 prostate cancer. A progression-free and overall 5-year survival of 70% and 90%, respectively, compares favorably to Radiation Therapy Oncology Group neoadjuvant trial outcomes for this stage of prostate cancer. References 1 : Radical perineal prostatectomy subsequent to bilateral orchiectomy. Delaware Med J1944; 16: 19. Google Scholar 2 : Endocrine therapy in carcinoma of the prostate; preparation of patients for radical perineal prostatectomy. JAMA1947; 134: 848. Crossref, Medline, Google Scholar 3 : Hormone control therapy as a preparation for radical perineal prostatectomy in advanced carcinoma of the prostate. New York J Med1949; 49: 629. Medline, Google Scholar 4 : Combined hormonal control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: a retrospective study based upon 25 years of experience. J Urol1968; 101: 86. Link, Google Scholar 5 : Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol2002; 167: 112. Link, Google Scholar 6 Pilepich M., Winter K., Byhardt R.W., Mesic J.B., Machtay M., Hanks G. E. et-al.: Androgen ablation adjuvant to definitive radiotherapy in carcinoma of the prostate: year 2000 update of RTOG phase III studies 86-10 and 85-31. Presented at annual meeting of ASTRO, abstract 114, 2000 Google Scholar 7 : RTOG protocol 92-02: a phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. J Rad Oncol Biol Phys2000; 48: 110. Google Scholar 8 : Neoadjuvant hormone therapy and external beam radiation for localized prostate cancer: Vancouver Island Cancer Centre experience. Can J Urol2000; 7: 937. Medline, Google Scholar 9 : Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology1995; 45: 616. Crossref, Medline, Google Scholar 10 : Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. Urology2000; 56: 289. Crossref, Medline, Google Scholar 11 : High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer. Br J Urol1995; 75: 771. Crossref, Medline, Google Scholar From the Wayne State University Medical Center, Detroit, Michigan, Southwest Oncology Group Statistical Center, Seattle, Washington, University of Colorado, Denver, Colorado, Oregon Health Sciences University, Portland, Oregon, State University of New York, Syracuse, New York, San Francisco UCOP, San Francisco and University of California, Davis, Sacramento, California, and Brook Army Medical Center/Wilford Hall Medical Center and University of Texas Health Science Center, San Antonio, San Antonio, Texas© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited by Wang X, Han B, Dou B, Gao L, Sun F, Qi M, Zhang J and Hu J (2023) A trio of tumor suppressor miRNA downregulates CREB5 dependent transcription to modulate neoadjuvant hormonal therapy sensitivityNeoplasia, 10.1016/j.neo.2022.100875, VOL. 36, (100875), Online publication date: 1-Feb-2023. Wang X, Zhang J and Han B (2022) Neoadjuvant Hormonal Therapy for Prostate Cancer: Morphologic Features and Predictive Parameters of Therapy ResponseAdvances in Anatomic Pathology, 10.1097/PAP.0000000000000347, VOL. 29, NO. 4, (252-258), Online publication date: 1-Jul-2022. Battisti N, Mislang A, Cooper L, O'Donovan A, Audisio R, Cheung K, Sarrió R, Stauder R, Soto-Perez-de-Celis E, Jaklitsch M, Williams G, O'Hanlon S, Alam M, Cairo C, Colloca G, Gil L, Sattar S, Kantilal K, Russo C, Lichtman S, Brain E, Kanesvaran R and Wildiers H (2020) Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working GroupJournal of Geriatric Oncology, 10.1016/j.jgo.2020.07.008, VOL. 11, NO. 8, (1190-1198), Online publication date: 1-Nov-2020. Kato M, Hirakawa A, Kobayashi Y, Yamamoto A, Ishida R, Kamihira O, Sano T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Hattori R, Gotoh M and Tsuzuki T (2019) Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patientsThe Prostate, 10.1002/pros.23942, VOL. 80, NO. 3, (284-290), Online publication date: 1-Feb-2020. Ryan S, Patel D, Parsons J and McKay R (2020) Neoadjuvant Approaches Prior To Radical ProstatectomyThe Cancer Journal, 10.1097/PPO.0000000000000424, VOL. 26, NO. 1, (2-12), Online publication date: 1-Jan-2020. Isaacsson Velho P, Lim D, Wang H, Park J, Kaur H, Almutairi F, Carducci M, Denmeade S, Markowski M, Isaacs W, Antonarakis E, Pritchard C, Eisenberger M and Lotan T (2019) Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical ProstatectomyJCO Precision Oncology, 10.1200/PO.19.00081, NO. 3, (1-13), Online publication date: 1-Dec-2019. Slaoui A, Albisinni S, Aoun F, Assenmacher G, Al Hajj Obeid W, Diamand R, Regragui S, Touzani A, Bakar A, Mesfioui A, Karmouni T, Ameur A, Elkhader K, Koutani A, Ibnattya A, Roumeguere T and Peltier A (2019) A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?World Journal of Urology, 10.1007/s00345-019-02652-7, VOL. 37, NO. 11, (2343-2353), Online publication date: 1-Nov-2019. Taneja S (2019) Re: Evaluation of Intense Androgen Deprivation before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide with or without AbirateroneJournal of Urology, VOL. 202, NO. 4, (662-662), Online publication date: 1-Oct-2019. Albisinni S, Aoun F, Diamand R, Al-Hajj Obeid W, Porpiglia F, Roumeguère T and De Nunzio C Cytoreductive prostatectomy: what is the evidence? A systematic reviewMinerva Urologica e Nefrologica, 10.23736/S0393-2249.18.03319-2, VOL. 71, NO. 1 Metcalfe M, Smaldone M, Lin D, Aparicio A and Chapin B (2017) Role of radical prostatectomy in metastatic prostate cancer: A reviewUrologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2017.01.001, VOL. 35, NO. 4, (125-134), Online publication date: 1-Apr-2017. Hagiwara K, Tobisawa Y, Kaya T, Kaneko T, Hatakeyama S, Mori K, Hashimoto Y, Koie T, Suda Y, Ohyama C and Yoneyama T (2017) Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate CancerInternational Journal of Molecular Sciences, 10.3390/ijms18020261, VOL. 18, NO. 2, (261) Kaushik D, Boorjian S, Thompson R, Eisenberg M, Carlson R, Bergstralh E, Frank I, Gettman M, Tollefson M and Karnes R (2016) Oncological outcomes following radical prostatectomy for patients with pT4 prostate cancerInternational braz j urol, 10.1590/s1677-5538.ibju.2016.0290, VOL. 42, NO. 6, (1091-1098), Online publication date: 1-Dec-2016. Joung J, Kim J, Kim S, Seo H, Chung J, Park W, Hong E and Lee K (2015) The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancerBMC Urology, 10.1186/s12894-015-0079-5, VOL. 15, NO. 1, Online publication date: 1-Dec-2015. Santen R, Duska L and Culp S (2014) Hormone Responsive Cancers Yen & Jaffe's Reproductive Endocrinology, 10.1016/B978-1-4557-2758-2.00029-9, (651-698.e14), . Rogers C, Sammon J, Sukumar S, Diaz M, Peabody J and Menon M (2013) Robot assisted radical prostatectomy for elderly patients with high risk prostate cancerUrologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2010.11.018, VOL. 31, NO. 2, (193-197), Online publication date: 1-Feb-2013. Naiki T, Kawai N, Okamura T, Nagata D, Kojima Y, Akita H, Yasui T, Tozawa K and Kohri K (2012) Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomyBMC Urology, 10.1186/1471-2490-12-36, VOL. 12, NO. 1, Online publication date: 1-Dec-2012. Berglund R, Tangen C, Powell I, Lowe B, Haas G, Carroll P, Canby-Hagino E, deVere White R, Hemstreet G, Crawford E, Thompson I and Klein E (2012) Ten-year Follow-up of Neoadjuvant Therapy with Goserelin Acetate and Flutamide Before Radical Prostatectomy for Clinical T3 and T4 Prostate Cancer: Update on Southwest Oncology Group Study 9109Urology, 10.1016/j.urology.2011.11.019, VOL. 79, NO. 3, (633-637), Online publication date: 1-Mar-2012. Picard J, Golshayan A, Marshall D, Opfermann K and Keane T (2012) The multi-disciplinary management of high-risk prostate cancerUrologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2009.09.002, VOL. 30, NO. 1, (3-15), Online publication date: 1-Jan-2012. Meng M and Carroll P (2012) Treatment of Locally Advanced Prostate Cancer Campbell-Walsh Urology, 10.1016/B978-1-4160-6911-9.00107-9, (2903-2920.e5), . Hsiao W, Moses K, Goodman M, Jani A, Rossi P and Master V (2010) Stage IV Prostate Cancer: Survival Differences in Clinical T4, Nodal and Metastatic DiseaseJournal of Urology, VOL. 184, NO. 2, (512-518), Online publication date: 1-Aug-2010. You D, Jeong I and Kim C (2010) Role of Radical Prostatectomy for High-Risk Prostate CancerKorean Journal of Urology, 10.4111/kju.2010.51.9.589, VOL. 51, NO. 9, (589), . Marusic G, Vojinov S and Levakov I (2010) Treatment of locally advanced prostatic cancerMedicinski pregledMedical review, 10.2298/MPNS1010689M, VOL. 63, NO. 9-10, (689-695), . Kusumi T, Koie T, Tanaka M, Matsumoto K, Sato F, Kusumi A, Ohyama C and Kijima H (2008) Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapyPathology International, 10.1111/j.1440-1827.2008.02294.x, VOL. 58, NO. 11, (687-694), Online publication date: 1-Nov-2008. Patel H, Amodeo A and Joseph J (2014) Salvage laparoscopic surgery in advanced prostate cancer: is it possible or beneficial?Expert Review of Anticancer Therapy, 10.1586/14737140.8.9.1509, VOL. 8, NO. 9, (1509-1513), Online publication date: 1-Sep-2008. Mazhar D and Waxman J (2008) Early chemotherapy in prostate cancerNature Clinical Practice Urology, 10.1038/ncpuro1204, VOL. 5, NO. 9, (486-493), Online publication date: 1-Sep-2008. Zelefsky M, Yamada Y, Kollmeier M, Shippy A and Nedelka M (2008) Long-Term Outcome Following Three-Dimensional Conformal/Intensity-Modulated External-Beam Radiotherapy for Clinical Stage T3 Prostate CancerEuropean Urology, 10.1016/j.eururo.2007.12.030, VOL. 53, NO. 6, (1172-1179), Online publication date: 1-Jun-2008. Vaishampayan U and Hussain M (2014) Update in systemic therapy of prostate cancer: improvement in quality and duration of lifeExpert Review of Anticancer Therapy, 10.1586/14737140.8.2.269, VOL. 8, NO. 2, (269-281), Online publication date: 1-Feb-2008. Fournier G, Valeri A, Mangin P and Cussenot O (2008) Cancer de la prostate. TraitementEMC - Urologie, 10.1016/S1762-0953(06)75038-5, VOL. 1, NO. 1, (1-20), Online publication date: 1-Jan-2008. Van Poppel H, Joniau S and Haustermans K (2007) Place de la chirurgie dans les cancers de la prostate de stades cT3-4 N0M0Cancer/Radiothérapie, 10.1016/j.canrad.2007.10.003, VOL. 11, NO. 8, (483-489), Online publication date: 1-Dec-2007. Van Poppel H, Joniau S and Haustermans K (2007) Surgery alone for advanced prostate cancer?European Journal of Cancer Supplements, 10.1016/S1359-6349(07)70036-8, VOL. 5, NO. 5, (157-169), Online publication date: 1-Sep-2007. Pu X, Wang X, Wu Y and Wang H (2007) Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomyJournal of Cancer Research and Clinical Oncology, 10.1007/s00432-007-0204-2, VOL. 133, NO. 8, (555-562), Online publication date: 1-Aug-2007. Loeb S, Smith N, Roehl K and Catalona W (2007) Intermediate-Term Potency, Continence, and Survival Outcomes of Radical Prostatectomy for Clinically High-Risk or Locally Advanced Prostate CancerUrology, 10.1016/j.urology.2007.02.054, VOL. 69, NO. 6, (1170-1175), Online publication date: 1-Jun-2007. Namiki K and Rosser C (2007) Neoadjuvant therapy and prostate cancer: what a urologist should knowCurrent Opinion in Urology, 10.1097/MOU.0b013e3280e08802, VOL. 17, NO. 3, (188-193), Online publication date: 1-May-2007. Engel J and Schally A (2007) Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormoneNature Clinical Practice Endocrinology & Metabolism, 10.1038/ncpendmet0399, VOL. 3, NO. 2, (157-167), Online publication date: 1-Feb-2007. Pendleton J, Pisters L, Nakamura K, Anai S and Rosser C (2007) Neoadjuvant therapy before radical prostatectomy: Where have we been? Where are we going?Urologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2006.03.005, VOL. 25, NO. 1, (11-18), Online publication date: 1-Jan-2007. Hsu C, Joniau S, Oyen R, Roskams T and Van Poppel H (2007) Outcome of Surgery for Clinical Unilateral T3a Prostate Cancer: A Single-Institution ExperienceEuropean Urology, 10.1016/j.eururo.2006.05.024, VOL. 51, NO. 1, (121-129), Online publication date: 1-Jan-2007. Dotan Z and Ramon J Staging of Prostate Cancer Prostate Cancer, 10.1007/978-3-540-40901-4_8, (109-130) Larré S, Salomon L and Abbou C Choices for Surgery Prostate Cancer, 10.1007/978-3-540-40901-4_10, (163-178) Johnstone P, Ward K, Goodman M, Assikis V and Petros J (2006) Radical prostatectomy for clinical T4 prostate cancerCancer, 10.1002/cncr.21926, VOL. 106, NO. 12, (2603-2609), Online publication date: 15-Jun-2006. Maldonado-Valadez R, Teber D, Erdogru T, Safi K, Frede T and Rassweiler J (2018) The Impact of Neoadjuvant Hormonal Therapy on the Outcome of Laparoscopic Radical Prostatectomy: A Matched Pair AnalysisJournal of Urology, VOL. 175, NO. 6, (2092-2096), Online publication date: 1-Jun-2006. Fournier G, Valeri A, Mangin P and Cussenot O (2005) Cáncer de próstata. TratamientoEMC - Urología, 10.1016/S1761-3310(05)43097-2, VOL. 37, NO. 1, (1-24), . Fournier G, Valeri A, Mangin P and Cussenot O (2004) Cancer de la prostate. TraitementAnnales d'Urologie, 10.1016/j.anuro.2004.06.004, VOL. 38, NO. 5, (225-258), Online publication date: 1-Oct-2004. Cooperberg M, Lubeck D, Meng M, Mehta S and Carroll P (2004) The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary ManagementJournal of Clinical Oncology, 10.1200/JCO.2004.10.062, VOL. 22, NO. 11, (2141-2149), Online publication date: 1-Jun-2004. Thompson I (2018) Balancing Cure and Quality of Life After Radical ProstatectomyJournal of Urology, VOL. 171, NO. 2, (717-718), Online publication date: 1-Feb-2004. Amling C (2004) How the Addition of Hormones Improves Outcome: Hormone Therapy and SurgeryEuropean Urology Supplements, 10.1016/j.eursup.2003.12.007, VOL. 3, NO. 1, (27-31), Online publication date: 1-Feb-2004. Gomella L, Zeltser I and Valicenti R (2003) Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancerUrology, 10.1016/j.urology.2003.10.025, VOL. 62, (46-54), Online publication date: 1-Dec-2003. Moul J and Fowler J (2003) Evolution of therapeutic approaches with luteinizing hormone–releasing hormone agonists in 2003Urology, 10.1016/j.urology.2003.10.014, VOL. 62, NO. 6, (20-28), Online publication date: 1-Dec-2003. Hellerstedt B and Pienta K (2003) The truth is out there: an overall perspective on androgen deprivationUrologic Oncology: Seminars and Original Investigations, 10.1016/S1078-1439(03)00046-2, VOL. 21, NO. 4, (272-281), Online publication date: 1-Jul-2003. Skinner E and Glode L (2003) High-risk localized prostate cancer: primary surgery and adjuvant therapyUrologic Oncology: Seminars and Original Investigations, 10.1016/S1078-1439(03)00018-8, VOL. 21, NO. 3, (219-227), Online publication date: 1-May-2003. Volume 168Issue 5November 2002Page: 2016-2019 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordsprostatectomyneoadjuvant therapyprostatic neoplasmsMetrics Author Information ISAAC J. POWELL More articles by this author CATHERINE M. TANGEN More articles by this author GARY J. MILLER Deceased. More articles by this author BRUCE A. LOWE More articles by this author GABRIEL HAAS More articles by this author PETER R. CARROLL Financial interest and/or other relationship with Ablation Technologies, AstraZeneca, National Cancer Institute, Southwest Oncology Group and Tap Pharmaceuticals. More articles by this author MICHAEL B. OSSWALD More articles by this author RALPH deVERE WHITE More articles by this author IAN M. THOMPSON Financial interest and/or other relationship with Amgen, AstraZeneca, Cytogen, Medical Educational Collaborative, Merck, Mission Pharmacal, National Cancer Institute, Pfizer and Tap Pharmaceuticals. More articles by this author E. DAVID CRAWFORD More articles by this author Expand All Advertisement PDF downloadLoading ...